Biomarker data from patients before starting with biological therapies (anti-interleukin (IL)-5 and anti-IgE)
| UK | Belgium | Spain | Poland | Netherlands | Hungary | Slovenia | Denmark | Sweden | Italy | Germany | |
| Before starting anti-IL-5 | |||||||||||
| Blood eosinophils ×109 L−1 | 0.400 (0.300–0.700) | 0.490 (0.320–0.760) | 0.530 (0.330–0.830) | 0.450 (0.405–0.855) | 0.360 (0.165–0.610) | 0.685 (0.233–1.010) | 0.440 (0.280–0.670) | 0.27 (0.100–0.600) | 0.800 (0.600–1.000) | NA | NA |
| Serum total IgE IU·mL−1 | 129 (44–404) | 270 (90–376) | 431 (168–594) | 405 (360–791) | 140 (48–366) | 56 (29–200) | 149 (53–256) | 164 (58–342) | 275 (115–820) | NA | NA |
| FENO ppb | 54 (31–81) | 43 (32–48) | 48 (40–70) | 27 (20–47) | 36 (24–60) | 52 (34–135) | 89.5 (55–101) | 38 (30–56) | 57 (29–80) | NA | NA |
| Before starting anti-IgE | |||||||||||
| Blood eosinophils ×109 L−1 | 0.300 (0.100–0.500) | 0.250 (0.166–0.310) | 0.420 (0.200–0.600) | 0.220 (0.100–0.510) | NA | 0.210 (0.150–0.438) | 0.235 (0.150–0.370) | 0.130 (0.100–0.300) | NA | NA | NA |
| Serum total IgE IU·mL−1 | 324 (139–567) | 238 (107–626) | 243 (114–515) | 154 (74–388) | NA | 172 (118–233) | 118 (32–795) | 148 (92–228) | NA | NA | NA |
| FENO ppb | 39 (24–82) | 29 (16–41) | 36 (20–57) | NA | NA | 34 (27–80) | 75 (41–92) | 10 (12–30) | NA | NA | NA |
Data are represented as median (interquartile range). FENO: exhaled nitric oxide fraction; NA: not available.